Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study estimates. But experts urge caution.

often rely on over-the-counter medications called anticholinergics, such as Benadryl and Unisom. Anticholinergics induce drowsiness and block the action of acetylcholine, an important ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

help Eisai and Biogen differentiate Leqembi from Eli Lilly's recently approved rival Kisunla (donanemab), and potentially speed up take-up of their drug, which remains fairly sluggish. Lilly has ...

Management acknowledged the impact of Medicare Part D redesign but highlighted mitigating factors such as strong oncology drug performance and cost-control measures. Regulatory delays for LEQEMBI ...

By early 2024, only 2,000 patients had been treated with Leqembi — fewer than the number that participated in clinical trials. The FDA waved through Eli Lilly’s look-alike drug Kisunla in 2024.